Adamax vs Follistatin
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
AdamaxAnabolic & IGF
Follistatin- Summary
- Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
- Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
- Half-Life
- Estimated 1-3 hours (short; peptide degradation)
- ~3–5 hours (endogenous form)
- Admin Route
- Subcutaneous, Intranasal (research)
- IM, SubQ
- Research
- —
- —
- Typical Dose
- 200-400 mcg per dose
- 50–100 mcg per injection site
- Frequency
- Once daily or every other day
- Every other day or 2–3x per week
- Key Benefits
- Proposed enhancement of learning and memory consolidation
- Neuroprotective via BDNF-TrkB pathway support
- May improve mood and resilience to stress
- Potential support for neurogenesis
- Cognitive clarity and focus enhancement (reported anecdotally)
- Explored for neurodegeneration and age-related cognitive decline
- Potent myostatin inhibition enabling supraphysiological muscle growth
- Increases skeletal muscle mass and fiber size
- May accelerate recovery from muscle injury
- Potential benefits in muscular dystrophy and sarcopenia
- Synergistic with IGF-1 and growth hormone in anabolic protocols
- Animal studies show dramatic increases in muscle mass
- Reduces muscle fibrosis in dystrophic models
- Side Effects
- Limited human safety data; largely anecdotal reports
- Possible headache or mild overstimulation
- Sleep disruption with late-day dosing
- Unknown long-term safety profile
- Potential for excessive muscle growth if doses are not controlled
- FSH suppression with implications for fertility in women
- Theoretical risk of cardiac hypertrophy with prolonged high-dose use
- Limited human safety data available
- +1 more
- Stacks With
- —
- —